University of Oklahoma Health Sciences Center
Oklahoma City, OK
Accepting patients
Iberdomide vs. Observation Post Ide-Cel CAR-T
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
- CELMoD
- Maintenance
- Randomization
- Phase 2
Accepting patients
Belantamab Mafodotin Combination Therapy
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1/2
Not yet accepting
Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
- Monoclonal Antibody
- CD38
- Randomization
- Maintenance
- Phase 3
Accepting patients
TECVAYLI
A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma
- CELMoD
- Bispecific Antibody
- BCMA
- Phase 1
2 hidden based on your filters.Show All